Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin  by Craig, Christine D. et al.
Gynecologic Oncology Reports 5 (2013) 64–66
Contents lists available at SciVerse ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /gynorCase ReportExtensive cutaneous metastases of ovarian cancer after prolonged
response to liposomal doxorubicin☆☆,☆☆☆Christine D. Craig a, David A. Iglesias b, Jack Watkins c, Robert L. Coleman b, Larry Kilgore d, Pedro T. Ramirez b,⁎
a Department of Obstetrics and Gynecology, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA
b Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
c Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
d Department of Gynecologic Oncology, University of Tennessee College of Medicine, Knoxville, TN 37920, USA☆☆ The University of Texas MD Anderson Cancer Cen
National Institutes of Health through Cancer Center Sup
☆☆☆ Précis: Cutaneous metastases from ovarian canc
with potentially severe morbidity. Such metastases p
challenge.
⁎ Corresponding author at: Department of Gyneco
University of Texas MD Anderson Cancer Center, 1515
77030, USA. Fax: +1 713 792 7586.
E-mail address: peramire@mdanderson.org (P.T. R
2211-338X © 2013 The Authors. Published by Elsevier
http://dx.doi.org/10.1016/j.gynor.2013.05.005a r t i c l e i n f o 5.1% of patients [3]. Cutaneous metastases are often a late manifesta-Article history:
Received 30 March 2013
Accepted 11 May 2013
Available online 19 May 2013
Keywords:
Ovarian cancer
Skin recurrence
Liposomal doxorubicin
tion of the disease and have a propensity to occur within previous
surgical scars, although cases of cutaneous metastases to the limbs
have also been reported. Cutaneous metastases most commonlyman-
ifest as small nodular lesions but can also manifest as herpetiform er-
ythematous lesions and scarring plaques.
Treatment of recurrent metastatic ovarian cancer involves system-
ic chemotherapy with agents chosen on the basis of previously
demonstrated platinum sensitivity or resistance. Pegylated liposomal
doxorubicin (PLD) is a cytotoxic agent that has demonstrated efﬁcacyIntroduction
In 2012, an estimated 22,280 women were diagnosed with ovarian
cancer and 15,500 died of the disease [1]. Approximately seventy-ﬁve
percent of women diagnosed with ovarian cancer in the United States
have stage III or more advanced disease at diagnosis. Althoughmost pa-
tients respond to initial treatment, the rate of recurrence after initial
treatment of ovarian cancer is as high as 65% to 75%. Themost common
site of recurrence is within the peritoneal cavity. In a postmortem
study, Rose et al. evaluated the patterns of ovarian cancer metastasis
and found that the most common sites of metastasis were the perito-
neal cavity, paraaortic lymph nodes, large intestine, pelvic lymph
nodes, and liver [2].
Ovarian cancer can metastasize by direct extension and transport
throughout the peritoneal cavity and/or through lymphatic or hema-
togenous spread. Cutaneous metastases are rare, occurring in 1.9% toter is supported in part by the
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er are rare and are associated
resent a clinical therapeutic
logic Oncology, Unit 1362, The
Holcombe Blvd., Houston, TX
amirez).
Inc. Open access under CC BY-NC-ND licensein the treatment of recurrent platinum-sensitive and platinum-
resistant ovarian cancer. In patients with platinum-resistant ovarian
cancer, PLD as a single agent has shown a survival beneﬁt nearly equal
to what is observed with other cytotoxic agents but is associated with
less toxicity. Given these ﬁndings and its relatively convenient dosing,
PLD is often chosen as the preferred agent for patients with recurrent
platinum-resistant ovarian cancer.Case
A64-year-oldwomanwas diagnosedwith at least stage IAhigh-grade
serous ovarian carcinoma following a laparoscopic bilateral salpingo-
oophorectomy. The patient was subsequently referred to The University
of Texas MD Anderson Cancer Center for further treatment. Initial evalu-
ation by computed tomography (CT) demonstrated indeterminate
subcentimeter liver lesions and a 1.8 cm lesion along the right external
iliac vessels. As such, the patient was treated with six cycles of paclitaxel
(175mg/m2) and carboplatin (AUC = 5), whichwere completed inMay
2006. She had no evidence of disease upon completion of therapy. The
patient underwent BRCA testing which demonstrated no detectable mu-
tations or large gene rearrangements.
Approximately 5 months after completion of therapy, CT revealed
disease recurrence in the form of a 1-cm subcutaneous nodule involv-
ing the left rectus abdominus muscle and small peritoneal deposits
within the pelvis and a lesion on the right external iliac vessels. The
serum CA-125 level was 7.1 U/mL. Given that disease had recurred
within 5 months of platinum-based therapy, the decision was made
to treat the patient with single-agent PLD (40 mg/m2) every
28 days. The patient experienced an infusion reaction with the ﬁrst
cycle, and consequently the dose was reduced to 35 mg/m2. In October
2009, the patient had completed a total of 34 cycles of treatment with.
Fig. 2. Cutaneous metastases on the abdominal wall in a patient with recurrent ovarian
cancer.
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course of treatment with PLD, periodic CT had demonstrated a stable
metastatic focus adjacent to the left rectus abdominus muscle. To
evaluate whether this residual lesion was metabolically active, posi-
tron emission tomography (PET)-CT was performed before therapy
was stopped. The focus was not ﬂuorodeoxyglucose avid and thus
was judged not to represent active disease. The CA-125 level was
11.4 U/mL. Chemotherapy was stopped, and the patient was placed on
surveillance.
In April 2010, follow-up PET-CT revealed new metastases in the
omentum and peritoneum. In May 2010, the patient underwent an ex-
ploratory laparotomy, total abdominal hysterectomy, omentectomy,
splenectomy, resection of a right-sided pelvic wall mass, resection of
anterior abdominal wall nodule, and optimal tumor-reductive surgery.
The ﬁnal pathology report after that surgery indicated high-grade
serous carcinoma in the omentum and anterior abdominal wall nodule.
In June 2010, PLD at 35 mg/m2 every 28 days was reinitiated; the
patient received an additional 8 cycles of this treatment.
In February 2011, PET-CT showed low-grade FDG uptake in a peri-
toneal nodule as well as new subcutaneous nodules that were too
small to characterize. In March 2011, treatment was changed to
letrozole 2.5 mg by mouth daily. The patient was treated with
letrozole for 2 months. In May 2011, reassessment with PET-CT dem-
onstrated progression of disease with enlargement of peritoneal im-
plants and subcutaneous nodules. The CA-125 level was 166.6 U/mL.
At that time, the patient was switched from letrozole back to PLD, but
in July 2011, after the patient had received two cycles of this drug,
PLD was discontinued because of a national drug shortage. The patient
was subsequently treated with tamoxifen 20 mg twice daily. Two
months later, she was changed to single-agent etoposide administered
in 21-day cycles consisting of 50 mg by mouth for 2 weeks followed
by a 1-week break.
After 2 months of treatment with etoposide, the patient noted
progression of subcutaneous disease in the suprapubic region. In
December 2011, etoposide was stopped, and the patient received 13
fractions of localized radiation at an outside facility. The CA-125
level at this time was 1133 U/mL (Fig. 1). After completion of radia-
tion therapy, PLD was restarted. After the patient had received an
additional four cycles of PLD, for a cumulative total of 48 cycles, PLD
was stopped and single-agent paclitaxel (60 mg/m2 weekly) was
started because of concerns about radiation recall and progression
of the abdominal wall and cutaneous disease. The patient received
one cycle of paclitaxel. She had progression of disease and was then
switched to a combination of cyclophosphamide and bevacizumab
at an outside institution. She completed three cycles of this treatment
and was noted to have progression of disease with extensive cutane-
ous involvement of the abdominal wall with multiple nodular and0
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Fig. 1. CA-125 level over the course of the patient's treatmentwith various chemotherapy
agents.ulcerative lesions on gross abdominal inspection (Fig. 2) and on
PET-CT (Fig. 3). The wound care team at MD Anderson evaluated
the patient's multiple and conﬂuent abdominal wall lesions. Wound
care specialists recommended daily cleansing of the wounds with sa-
line followed by application of Xeroform and Aquaphor ointment to
affected areas. The patient was referred to hospice care in August
2012. Two months after referral to hospice, she died.Comment
Robinson et al. recently reported that in a series of 233 patients
with recurrence after treatment for stage III ovarian cancer, only
two patients (0.8%) had recurrence in cutaneous tissue [4]. Another
group documented six cases of cutaneous metastases (0.9%) in 645
patients diagnosed with epithelial ovarian carcinoma [5]. The major-
ity of these cutaneous recurrences were within previous laparotomy
scars or drainage site scars. All studies of cutaneous metastases that
were reviewed showed that such metastases from any visceral
organ are associated with a very poor prognosis. Survival has been
reported to be anywhere from 3 to 8 months after diagnosis of a cu-
taneous lesion in ovarian cancer.Fig. 3. Axial positron emission tomography image demonstrating ﬂuorodeoxyglucose-
avid lesions within the subcutaneous tissue of the lower abdomen.
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lapse, which is associated with poor long-term survival. Approxi-
mately 20% of patients with relapse have platinum-resistant disease.
PLD is a preferred treatment for such patients because it is among
the non-platinum-based agents with the highest activity against re-
current platinum-resistant ovarian cancer. Etoposide is another
agent with similar efﬁcacy [6]. In the event that the patient cannot
tolerate the cytotoxic nature of these drugs, hormonal agents such
as letrozole and tamoxifen have proven effective in certain subtypes
of platinum resistant disease [7,8]. However, the role of these agents,
especially PLD, in the management of cutaneous metastases has not
been fully evaluated.
Management of cutaneous metastases varies widely and remains a
clinical challenge, especially if primary excision is not feasible because
of the location or extent of disease. Previously evaluated systemic
chemotherapies have had minimal effect. Earlier studies suggested
that electrocoagulation, electron beam therapy, and phototherapy
may be effective in treating cutaneous lesions. At present, the topical
Toll-like receptor 7 agonist imiquimod and electrochemotherapy are
being studied for treatment of cutaneous metastases. Imiquimod
exerts its effects by activating local macrophages through its binding
of toll-like receptor 7, which leads to release of pro-inﬂammatory
cytokines that are responsible for the cytotoxicity of this drug [9].
Electrochemotherapy, historically used in the treatment of metastatic
head and neck cancers, has been explored in the treatment of cutane-
ous disease in patients with chest wall recurrence of breast cancer. In
electrochemotherapy, a local electrical current is applied to the lesion,
which causes cellular membranes to become more permeable to the
chemotherapy agent being used. In the case of bleomycin-based
electrochemotherapy, the electric current increases permeability to
the drug by 700-fold [10]. In a phase II study by Campana et al.,
bleomycin-based electrochemotherapy produced a complete re-
sponse in 54% of the patients, and 81% of the patients were alive
at 3 years [10]. However, it has been suggested that the aim ofelectrochemotherapy in patients with extensive disease is to maintain
stable disease. Limited data exist on the utility of this technology in
patients with cutaneous metastases from ovarian cancer.
In conclusion, cutaneous metastases from ovarian cancer are rare
and portend a poor prognosis. Management of cutaneous metastases
remains a clinical challenge. Further studies evaluating the role of
speciﬁc therapies are needed to guide treatment.
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